Epizyme (NASDAQ:EPZM) Upgraded at Morgan Stanley

Morgan Stanley upgraded shares of Epizyme (NASDAQ:EPZM) from an equal weight rating to an overweight rating in a research note released on Thursday, Benzinga reports. They currently have $22.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $12.00.

A number of other analysts have also issued reports on the company. BidaskClub lowered Epizyme from a buy rating to a hold rating in a research note on Wednesday, December 4th. HC Wainwright restated a buy rating on shares of Epizyme in a report on Thursday, October 31st. ValuEngine downgraded shares of Epizyme from a hold rating to a sell rating in a research note on Thursday, November 7th. Zacks Investment Research downgraded shares of Epizyme from a hold rating to a sell rating and set a $11.00 target price for the company. in a report on Monday, October 21st. Finally, Cowen reissued a buy rating and set a $18.00 price objective on shares of Epizyme in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Epizyme presently has an average rating of Buy and a consensus price target of $18.14.

Shares of Epizyme stock opened at $18.22 on Thursday. Epizyme has a fifty-two week low of $5.14 and a fifty-two week high of $18.40. The firm has a market cap of $1.66 billion, a PE ratio of -10.59 and a beta of 2.58. The business’s fifty day moving average is $14.00 and its two-hundred day moving average is $12.90. The company has a quick ratio of 10.90, a current ratio of 10.90 and a debt-to-equity ratio of 0.03.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.11. The business had revenue of $5.72 million for the quarter, compared to analysts’ expectations of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. Equities research analysts anticipate that Epizyme will post -1.89 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in EPZM. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Epizyme by 29.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 1,262 shares during the period. Aperio Group LLC acquired a new stake in shares of Epizyme during the second quarter worth approximately $72,000. Rockefeller Capital Management L.P. acquired a new stake in shares of Epizyme during the second quarter worth approximately $88,000. United Services Automobile Association bought a new stake in shares of Epizyme in the second quarter worth $134,000. Finally, HarbourVest Partners LLC bought a new stake in shares of Epizyme in the second quarter worth $177,000. 86.92% of the stock is currently owned by institutional investors.

About Epizyme

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Read More: Google Finance Portfolio

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.